Document is current
Any future updates will be listed below
-
Authors
Calin, Ruxandra https://orcid.org/0000-0001-6516-9825
Massari, Véronique
Pialoux, Gilles
Reydellet, Nelly
Plenel, Eve
Chauvin, Carole
Jauffret-Roustide, Marie
Day, Nesrine
Kreplak, Georges
Maresca, Anaenza Freire
Derche, Nicolas
Louis, Sandra
Pol, Stanislas
Doré, Véronique
Rouzioux, Christine
Chauvin, Pierre
-
Funding
Funding for this research was provided by:
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
Roche Laboratories
Gilead
- License Information
-
More Information
Article History
Received: 28 January 2020
Accepted: 9 November 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: A French ethical committee approved the study on July 25, 2013 (Comité de Protection des Personnes d’Hôtel-Dieu, Paris, France). The study was registered with the French National Agency for Drug Safety (ANSM) on June 5 2013 under the number 2013-A00840–45.Written consent was obtained from all study volunteers.
: Not Applicable.
: Dr. R Calin received grant fees from Bristol-Myers Squibb and consulting fees from Janssen, MSD and Bristol-Myers Squibb, none related to the ANRS CUBE study.Prof. G. Pialoux has received consulting fees from Gilead, Merck, Nephrotek, ViiVhealtcare, Abbvie, none related to the ANRS CUBE study.Prof. S Pol has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, Roche, MSD, MYR_Pharma, Shionogi, Biotest and Abbvie, and grants from Bristol-Myers Squibb, Gilead, Roche and MSD, none related to the ANRS CUBE study.The other authors declared no competing interest.
